Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- ELVN
- Price
- 27.03
- Stock movement down
- -0.17 (-0.64%)
- Company name
- Enliven Therapeutics Inc.
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 1.60B
- Ent value
- 1.52B
- Price/Sales
- 5076.45
- Price/Book
- 3.37
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -5.31%
- 1 year return (CAGR)
- 22.86%
- 3 year return (CAGR)
- -
- 5 year return (CAGR)
- -
- 10 year return (CAGR)
- -
Last updated: 2026-01-22
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
ELVN does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 5076.45 |
| Price to Book | 3.37 |
| EV to Sales | 4801.20 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 59.35M |
| EPS (TTM) | -1.57 |
| FCF per share (TTM) | -1.16 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 316.00K |
| Gross profit (TTM) | 3.00K |
| Operating income (TTM) | -112.27M |
| Net income (TTM) | -97.21M |
| EPS (TTM) | -1.57 |
| EPS (1y forward) | -1.98 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 0.95% |
| Operating margin (TTM) | -35528.16% |
| Profit margin (TTM) | -30761.71% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 101.73M |
| Net receivables | 0.00 |
| Total current assets | 482.68M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 2.01M |
| Total assets | 490.88M |
| Accounts payable | 1.43M |
| Short/Current long term debt | 387.00K |
| Total current liabilities | 14.65M |
| Total liabilities | 14.75M |
| Shareholder's equity | 476.12M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -71.67M |
| Capital expenditures (TTM) | 160.00K |
| Free cash flow (TTM) | -71.83M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -20.42% |
| Return on Assets | -19.80% |
| Return on Invested Capital | -20.40% |
| Cash Return on Invested Capital | -15.07% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 27.73 |
| Daily high | 28.69 |
| Daily low | 26.99 |
| Daily Volume | 1.47M |
| All-time high | 877.92 |
| 1y analyst estimate | 41.38 |
| Beta | 1.07 |
| EPS (TTM) | -1.57 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | 12 Mar 2026 |
Downside potential
Loading...
Downside potential data
| ELVN | S&P500 | |
| Current price drop from All-time high | -96.92% | -0.89% |
| Highest price drop | -98.30% | -19.00% |
| Date of highest drop | 10 Apr 2025 | 8 Apr 2025 |
| Avg drop from high | -97.58% | -2.49% |
| Avg time to new high | - | 6 days |
| Max time to new high | 322 days | 89 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
1.60B
Marketcap category
Small-cap
Description
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a CNS penetrant and irreversible HER2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 driven cancers and solid tumors. The company is headquartered in Boulder, Colorado.
Employees
65
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page